Inspira™ Technologies Reports Second Quarter 2022 Financial Results

 

As of June 30, 2022, the Company had $19.2 million in cash

RA'ANANA, Israel, Aug. 11, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today its financial results for the second quarter ended June 30, 2022.

 

Inspira Technologies Logo

 

Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: "The Company continues to meet its scheduled major objectives and improve its position within the target market of direct blood oxygenation. Our focus on contributing to medical advancement within this space is exemplified by the introduction of our new HYLA™, a non-invasive blood sensor being designed to perform real-time and continuous blood measurements. The HYLA™ is being designed to assist physicians in the monitoring of a patient's clinical condition, alerting of a sudden change in the patient's vital signs, which may require immediate medical attention and potentially save lives.

"Planned as a technically advanced component for the InspiraTM ART system, the HYLA™ will also have its own distinct target market and business model. Recently, Inspira also revealed the first public pictures of the ALICE™ Device, designed as a cardiopulmonary bypass (CPB) or heart-lung bypass device. We continue to strategically enhance our presence within the market as we prepare to enter the verification and validation (V&V) process with the U.S. Food and Drug Administration (FDA) approval of our technologies."  

Highlights:

  • April 6, 2022 - Inspira Technologies announced a deployment agreement for the InspiraTM ART system in the Israeli market to potentially target $15 million. The agreement is for a 7-year period and subject to regulatory approval. 
  • July 6, 2022 - Inspira Technologies announced the development of the HYLA™ Non-Invasive Blood Sensor designed to assist physicians in monitoring a patient's clinical condition, potentially targeting the $2.5 billion arterial blood gas (ABG) market.
  • July 7, 2022 - Inspira Technologies announced a strategic agreement in the U.S. with a potential value of $59 million for the deployment of 3,889 HYLA™ Blood Sensors. The agreement is for a three-year period and is subject to regulatory clearance.
  • July 11, 2022 - Inspira Technologies revealed the ALICE™ Device, designed as a cardiopulmonary bypass (CPB) or heart-lung bypass device, designed to oxygenate and circulate blood for up to 6 hours during cardiac surgery.

Financial Results for the Six Months Ended June 30, 2022

Research and development expenses for the six months ended June 30, 2022, were $4.3 million, compared to $1.1 million for the corresponding period in 2021. The increase is a result of the Company's recruitment of specialized manpower and the expanded development of its new technologies and operations.

Marketing expenses for the six months ended June 30, 2022, were $777,000, compared to $244,000 for the corresponding period in 2021. The increase is attributed to rises in marketing, payroll,and share-based compensation expenses. Marketing activities commenced in the first quarter of 2021 and became more intensive with the Company's need to create brand awareness and explore go-to-market capabilities.

General and administrative (G&A) expenses for the six months ended June 30, 2022, were $2.9 million, compared to $1.2 million for the corresponding period in 2021. The increase stemmed primarily from an uptick in payroll and related expenses, as well as costs associated with the Company's status as a publicly traded company following its initial public offering (IPO) on Nasdaq in July 2021, the increase in existing and new expenses included professional fees, director fees, and directors' and officers' insurance costs.

Finance income for the six months ended June 30, 2022, was $4.5 million, compared to expenses in the amount of $5.7 million for the corresponding period in 2021. The increase in finance income derived from the calculation of the fair value of the Company's financial equity liabilities to pre-IPO and IPO investors in addition to the fluctuation in the USD exchange rate during the first half of 2022.

Net loss for the six months ended June 30, 2022, was $3.5 million, compared to a net loss of $8.2 million for the six months ended June 30, 2021.

Financial highlights for the quarter ended June 30, 2022

Research and development expenses for the three months ended June 30, 2022, were $2.7 million, an increase of $1.2 million compared to the first quarter of 2022. The increase was attributed to share-based compensation expenses in addition to expected R&D expenditures on new technologies and new projects.

General and administrative expenses for the three months ended June 30, 2022, were $1.4 million, a non-material decrease of $0.2 million compared to the first quarter of 2022.

Sales and Marketing expenses for the three months ended June 30, 2022, were $0.3 million, a decrease of approximately $0.17 million compared to the first quarter of 2022.

Balance Sheet highlights

Cash, cash equivalents, and short-term bank deposits were $19.2 million as of June 30, 2022, compared to $23.7 million as of December 31, 2022.

Financial liabilities at fair value totaled $0.4 million as of June 30, 2022, compared to $3.2 million on December 31, 2021. The financial liabilities represent the fair value of the Company's equity liabilities to pre-IPO and IPO investors.

As of June 30, 2022, shareholders' equity totaled $17.8 million, compared to shareholders' equity totaling $20.3 million as of December 31, 2021.

Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (Inspira™ART), designed to rebalance patient oxygen saturation levels. The Company's technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's product has not yet been tested or used in humans and has not been approved by any regulatory entity.

For more information, please visit our corporate website: 
https://inspira-technologies.com/

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses meeting milestones in 2022 and the timing for such milestones, its various products in development and the benefits that such products may provide, its various strategic agreements and the potential amounts that may be derived under such agreements, all subject to regulatory approval. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2021 filed with the SEC, which is available on the SEC's website, www.sec.gov.

Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

For more details: 
Investor Relations, MS-IR LLC
Miri Segal,
+917-607-8654
msegal@ms-ir.com

US Public Relations 
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
IINN@redchip.com

MRK-ARS-033 Copyright © 2018-2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

UNAUDITED CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
(US dollars in thousands)

               
   

June 30,

   

December 31,

     
   

2022

   

2021

     
                 

ASSETS

                   

Current Assets:

                   

Cash and cash equivalents

   

14,154

     

23,749

     

Cash deposits

   

5,020

     

-

     

Other accounts receivable

   

195

     

639

     

Restricted cash

   

67

     

120

     

Total current assets

   

19,436

     

24,508

     
                     

Non-Current Assets:

                   

Right of use assets, net

   

1,101

     

1,160

     

Property, plant and equipment, net

   

208

     

202

     

Total non-current assets

   

1,309

     

1,362

     

Total Assets

   

20,745

     

25,870

     
                               

 

             
     

June 30,

December 31,

   
     

2022

   

2021

   
                 

LIABILITIES AND SHAREHOLDERS' EQUITY

                   

Current Liabilities:

                   

Trade accounts payables

     

50

     

93

   

Other accounts payable

     

1,114

     

725

   

Lease liabilities

     

309

     

281

   

Financial Liabilities at Fair Value

     

439

     

3,215

   

Total current liabilities

     

1,912

     

4,314

   
                     

Non-Current Liabilities:

                   

Lease liabilities

     

787

     

900

   

Loan from the Israeli Innovation Authority

     

293

     

302

   

Total non- current liabilities

     

1,080

     

1,202

   
                     

Shareholders' Equity:

                   

Share capital and premium

     

52,042

     

48,935

   

Foreign exchange reserve

     

(2,025)

     

210

   

Accumulated deficit

     

(32,264)

     

(28,791)

   

Total equity

     

17,753

     

20,354

   

Total Liabilities and Shareholders' Equity

     

20,745

     

25,870

   
                     
                                               

 

UNAUDITED CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE INCOME 
(US dollars in thousands)

             
     

For the Three Months
Ended June 30,

 

For the Six Months
Ended June 30,

 
   

  

2022

     

2021

   

 

 

2022

 

2021

 
                               

Research and development expenses

     

 

2,734

     

437

   

 

4,294

 

 

1,104

 

Marketing expenses

       

305

     

114

   

777

 

244

 

General and administrative expenses

       

1,392

     

389

   

 

2,936

 

 

1,210

 

Operating loss

       

4,431

     

940

   

8,007

 

2,558

 

Finance expenses (income)

       

(2,338)

     

59

   

(4,534)

 

5,732

 

Loss (profit) before tax

       

2,093

     

999

   

3,473

 

8,290

 

Taxes on income

                             

Loss (profit) for the period

     

2,093

     

999

   

 

3,473

 

 

8,290

 

Other comprehensive loss (profit), net of tax:

                             

Items that will not be reclassified to profit or loss:

                             

Exchange profits(losses) arising on translation to
presentation currency

   

(1,810)

     

182

   

 

 

(2,235)

 

 

 

(33)

 

Total comprehensive loss for the period

   

3,903

     

817

   

 

5,708

 

 

8,323

 
                                                   

 

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY 
(US dollars in thousands) 
For the Three-Month Period Ended June 30, 2022 (Unaudited):

   

Share capital
and premium

   

Adjustments arising from translating
financial operation

   

Accumulated
deficit

   

Total

   

Balance on March 31, 2022

                                 

Changes during the period:

   

50,189

     

(215)

       

(30,171)

     

19,803

 

Loss for the period

   

-

     

-

       

(2,093)

     

(2,093)

 

Other comprehensive loss

   

-

     

(1,810)

       

-

     

(1,810)

 

Total comprehensive loss

   

-

     

(1,810)

       

(2,093)

     

(3,903)

 

Share-based compensation

   

1,853

     

-

       

-

     

1,853

 

Balance on June 30, 2022

   

52,042

     

(2,025)

       

(32,264)

     

17,753

 
                                           

 

For the Six-Month Period Ended June 30, 2022 (Unaudited):

   

Share capital
and premium

   

Adjustments arising from translating
financial operation

   

Accumulated
deficit

   

Total

   

Balance on January 01, 2022

                                 

Changes during the period:

   

48,935

     

210

       

(28,791)

     

20,354

 

Loss for the period

   

-

     

-

       

(3,473)

     

(3,473)

 

Other comprehensive loss

   

-

     

(2,235)

       

-

     

(2,235)

 

Total comprehensive loss

   

-

     

(2,235)

       

(3,473)

     

(5,708)

 

Share-based compensation

   

3,107

     

-

       

-

     

3,107

 

Balance on June 30, 2022

   

52,042

     

(2,025)

       

(32,264)

     

17,753

 
                                           

 

 

 

Cision View original content:https://www.prnewswire.com/news-releases/inspira-technologies-reports-second-quarter-2022-financial-results-301604319.html

SOURCE Inspira Technologies

 
 
Company Codes: NASDAQ-NMS:IINN
 

Back to news